Dispersible formulation of levodopa-benserazide in treatment of 204 parkinson disease: a multicenter study
- VernacularTitle:弥散型左旋多巴-苄丝肼治疗帕金森病204例的多中心研究
- Author:
Zhongfang WENG
;
Xinde WANG
;
Yi LUO
;
Zhuolin LIU
;
Xiuchu SU
;
Zhenxin ZHANG
;
Yuping JIANG
;
Benshu ZHANG
;
Xiangru SUN
;
Shengdi CHEN
- Publication Type:Journal Article
- From:
Chinese Journal of New Drugs and Clinical Remedies
2001;20(2):97-100
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To study the efficacy and safety of dispersible formulation of levodopa-benserazide on the parkinson disease. METHODS: The multicenter, open-label, self-controlled trial was conducted at 23 hospitals in 15 cities. Two hundred and four patients with idiopathic parkinson who had received standard levodopa-benserazide previously participated in this study. Dispersible levodopa-benserazide instead of standard levodopa-benserazide for 8 wk as a course. The Webster rating scale and patient diary were applied to assess the efficacy and safety of dispersible levodopa-benserazide. RESULTS： The medication with dispersible levodopa-benserazide increased “on” time by 47 min, decreased “off” time by 11 min, and speeded the onset of “on” time by 37 min. The Webster score was improved by 25 %. Statistical significant difference was calculated (P<0.01). Slight and few adverse reactions were found. CONCLUSION: Dispersible formulation of levodopa-benserazide is a powerful anti-parkinsonian drug characterized by oral easy use and rapid reach to therapeutic action after ingestion. This drug is particularly used in the parkinsonian patients with morning akinesia, delayed onset of “on” time, afternoon “off” status and dysphagia.
